GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sakai Chemical Industry Co 4078.T · JPY

Materials · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

3,160

+1.94%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Sakai Chemical Industry Co

Its shares trade on Tokyo Stock Exchange under the ticker 4078.T. It has been listed since 23 March 1950. In the fiscal year to 31 March 2026, it reported revenue of ¥81.45bn and net income of ¥2.75bn. At that date it held total assets of ¥117.22bn and shareholders' equity of ¥77.71bn.

Sakai Chemical Industry Co., Ltd. engages in provision of chemical products. The company is headquartered in Sakai-Shi, Osaka-Fu. The firm operates in two business segments. Chemical segment is involved in the manufacture and sale of chemical products. Main products include titanium products, resin additives, barium products, catalyst products, electronic materials, zinc products, functional materials, and other chemicals such as organophosphorus compounds, organic sulfur compounds, as well as water treatment agents, among others. Medical segment is involved in the manufacture and sale of pharmaceuticals and quasi drugs. Main products include barium X-ray contrast media, medical drugs for peptic ulcer & reflux esophagitis, general drugs such as cold and gastrointestinal drugs, functional foods, as well as other products such as medical devices, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Materials
Industry
Chemicals
Listed since
23 Mar 1950
Employees
2,013

Leadership

Pay as last reported

  • Mr. Toshiyuki YaguraPresident, Executive Officer, Representative Director, since 2020
  • Mr. Wataru IbarakiExecutive OfficerChief Director of Sales, Director of Functional Materials Sales
  • Mr. Hiroyuki HattoriExecutive Officer, Chief Director of Business Strategy, Director of Accounting, Director, since 2020
  • Mr. Koichiro MagaraExecutive Officer, Chief Director of Research and Development, Director, since 2022
  • Mr. Yasuhiro OkamotoExecutive Officer, Chief Director of Production Technology, Manager of Onahama Plant, Director, since 2015
  • Mr. Akira MoriokaExecutive Officer, Chief Director of Administration
  • Mr. Hiroshi NakaoExecutive Officer, Deputy Chief Director of Main Research and Development Unit, Director of R&D Promotion in Main Research and Development Unit
  • Mr. Shinji OgamaExecutive Officer, Deputy Chief Director of Business Strategy, Director of Business Planning
  • Mr. Keiichi TabataExecutive Officer, Manager of Sakai Business Center
  • Mr. Hiroshi TokunagaExecutive Officer, Assistant Manager of Onahama Business Center, First Ohanama Business Plant Manager
  • Mr. Yoshikazu ItoIndependent Director
  • Mr. Mitsunori MatsudaIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Sakai Chemical Industry employs 2,013 full-time employees in Sakai-shi, Osaka-Fu.
  • Chemical segment offers titanium products, resin additives, and barium products.
  • Medical segment provides barium X-ray contrast media and medical drugs for peptic ulcer.

Weaknesses

  • Sakai Chemical operates in two business segments without specific market share data.
  • The company has no mention of digital transformation initiatives in its description.
  • Sakai Chemical's product range lacks innovation in electronic materials.

Opportunities

  • Sakai Chemical can expand its medical segment with functional foods and medical devices.
  • The chemical segment's organophosphorus compounds have potential in agricultural applications.
  • Sakai Chemical's water treatment agents can target growing environmental regulations.

Threats

  • Sakai Chemical faces competition from global chemical firms in titanium products.
  • Regulatory changes in Japan may impact medical drug approvals.
  • The chemical industry's volatility affects resin additives and barium products.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.